Details of the Drug

General Information of Drug (ID: DMAMTGI)

Drug Name
SD-101
Synonyms HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 3 [1]
Skin disease EA00-EM0Z Phase 2 [2]
Melanoma 2C30 Phase 1/2 [3]
Squamous cell carcinoma 2B60-2D01 Phase 1/2 [3]
Squamous head and neck cell carcinom 2D60.0 Phase 1/2 [4]
Drug Type
Oligonucleotide
Cross-matching ID
TTD ID
D08RJM
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Not Available [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hepatitis C virus infection
ICD Disease Classification 1E51.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 9 (TLR9) DTT TLR9 2.58E-01 -0.06 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02521870) A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
5 Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.